ABS0164 @ #ACR23 Is a virtual MSK test consistent & comparable to in-person assessments w/ regard to dz activity in f/u of RA pts? YES! Some variability in # of swollen joints but approach shown below had good reliability & acceptable lvl of agreement @RheumNow #ACRBEST https://t.co/yxpPb2Br4n

TM01 @ #ACR23: Daunting Case of Diarrhea 65 yo F w/ sero+RA + 2ndary SjS p/w 4 wks diarrhea -CT a/p: thickening of cecum, ascending colon -Colonoscopy path: ischemia -R colectomy: enterocoelic lymphocytic phlebitis, no underlying vasculitis. Dx: IgG4-RD, serum IgG4⬆️ @RheumNow https://t.co/jQ57U5EjPo

1-Can we prevent RA ? Vagotomy? 2-CV events in auto immune rheumatic disease pregnancies. 3-CVS vasculitis , challenges and role of Brain biopsy And others…….. https://t.co/BX8bDSX1M3 @RheumNow , daily recap #ACR23

20 years real-world data on disease burden, patient experience & unmet needs in Refractory #RheumatoidArthritis ▶️Higher glucocorticoid & opioid use ▶️Greater comorbidity & symptom burden ▶️More rheumatology visits #ACR23 👉🏽https://t.co/CAUorjQbvN by @KristinWipfler @Dr_K et al https://t.co/vx1aOZizfE

OMG! The #Gerirheum community is looking into this bias— pls fill out their survey @UnaMakris @SattuiSEMD https://t.co/Axaoo3WohH

Automated #deeplearning systems #ArtificialIntelligence identify & predict joint damage in hand radiographs from #RheumatoidArthritis patients ➡️May aid in monitoring joint damage #ACR23 👉🏽https://t.co/IcoZHY6lns https://t.co/mZWg6YIUp3

ABS0433: ⭐️Older adults w/ RA less likely to receive tx w/ DMARDs despite being well tolerated and effective ➡️Retrospect, obs using Medicare data ➡️At least 66 yo old w/ new dx of late-onset RA (LORA) 🚩If no contraindications, start DMARDs early in LORA! #ACR23 @RheumNow https://t.co/ChalcgtS2O

Super interesting study re: impact of ORAL SURVEILLANCE on prescribing Post safety report, JAK pts shifted younger w/lower comorbidities (esp CVD) I know many have mixed feelings, but I believe in the risk & support this type of shift @RheumNow Abstr0435 #ACR23 https://t.co/EBg9VOIbj1

ABS0450 ⭐️Baricitinib non-inferior as well as superior to TNFi in terms of ACR50 response @ 12w in real world csDMARD refractory RA patients ➡️open-label, T2T w/ Baricitinib (n=102) vs TNFi (n=97) ➡️DAS28-CRP remission (<0.6) in 74% of Bari vs 47% of TNFi #ACR23 @RheumNow https://t.co/yydS20hNzM